Epilepsy is a common and chronic neurological disease that is characterized by recurrent seizures which impose a major burden on patients, their caregivers, and society (, ). The aim of this Research Topic was thus to provide evidence that personalized translational epilepsy research will benefit patients through targeted experimental (), clinical and network research (, ). There is a fast growing number of publications that deal with personalized or precision approaches for the treatment of epilepsy, Figure 1.
Figure 1
People with epilepsy face disease-specific restrictions concerning self-sufficiency, mobility, career choice, family planning, and other social aspects (, ). An analysis of patients with severe drug-refractory epilepsy showed a seven-fold increase in mortality, along with high costs and frequent epilepsy-related accidents and injuries (Strzelczyk et al.). The authors used a German health insurance database to administer a top-down approach, drawing patients from a representative cohort and matched them to a cohort that was not affected. Comorbidities, like depression and vascular disorders, were significantly increased in patients with epilepsy (Strzelczyk et al.). Focusing on epilepsy-related accidents and injuries, Willems et al. used a bottom-up approach in a cross-sectional study, and it showed that there was a possibility of a reduced quality of life and increased depression scores in affected patients (Willems et al.). The presented data in both studies fits well with other recent burden-of-disease studies that showed the costs for hospital treatment and anticonvulsants as being major cost drivers (–) and that persisting seizures were also associated with a reduced quality of life (, ).
While the use of newer anticonvulsants may be associated with increased costs, it also has the potential to significantly reduce the seizure burden. Brivaracetam is the latest anticonvulsant that has been approved as an add-on therapy for the treatment of focal-onset seizures (). A single-center study from Marburg in Germany (Zahnert et al.) shows promising post-marketing results in a cohort of mainly drug-refractory patients, while another multi-center study focused on patients with epileptic encephalopathies (Willems et al.). In both studies, 50% responder rates of 35 to 45% were achieved, which were well in line with other postmarketing results (–).
The initial response to anticonvulsants is explored in patients with newly diagnosed epilepsy, and showed that the initial 6-month response, as well as the number of seizures prior to treatment and brain-imaging abnormalities, are important prognostic factors (Xia et al.).
Lifestyle-dependent factors are important, especially in genetic generalized epilepsies. Until now, it was unclear as to whether alcohol consumption has an impact on epilepsy in these patients (). Even if the risk is generally increased in patients with epilepsy, patients with genetic generalized epilepsies have a particularly high risk of alcohol related-seizures after the consumption of a large amount of alcohol. This can also be attributed to accompanying factors, such as altered sleep architecture or impaired adherence to antiepileptic medication (Hamerle et al.).
The genetic architecture of common non-lesional focal epilepsies was evaluated in a study that uses a customized panel of 21 well-known focal epilepsy genes (Tsai et al.). The study revealed that only 1.85% (11/593 patients) carried pathogenic or likely pathogenic variants in these genes, and this indicated that other yet to be discovered genes play a role as well.
Comorbidities, such as cognitive issues, are often present in patients with epilepsy (). Gorny et al. showed that not all scales that were used to assess global cognitive function, work reliably in patients with epilepsy.
Structural abnormalities associated with clinical and neuropsychological characteristics in genetic epilepsies was evaluated in two studies on juvenile myoclonic epilepsy (JME) using MRI diffusion tensor imaging (DTI), and in benign childhood epilepsy, with centrotemporal spikes (BECTS), which used the graph theory analysis based on the cortical gyrification index, respectively (Domin et al.; Jiang et al.). In JME, the extent of microstructural abnormalities within the subcortical networks, including cortico-cortical, thalamo-frontal, and cortico-spinal connections, determined the clinical manifestation and subtype of JME in the individual patient, such as photoparoxysmal responses or seizures with predominant motor symptoms (Domin et al.). In contrast, abnormal cortical folding that was mainly in the central region is presumably the neuroanatomical basis for BECTS (Jiang et al.). The findings of both studies are important steps for the establishing of the pathophysiological concepts found in genetic epilepsies.
A step forward in the care for people with epilepsy could be through the introduction of technological therapies. Page et al. pointed out in their perspective article that there has been an increase in patient-triggered interventions, a finding based on automated monitoring of indicators and risk factors facilitated by technological advances. The main goal of such interventions would be the reduction of epilepsy-related mortality with SUDEP (Sudden Unexpected Death in Epilepsy) being the main reason for epilepsy-related deaths (, ).
An important point on this road is the development of an automatic computer-based detection algorithm of seizures. In their review, Baumgartner et al. described the use of potential bio signals, such as scalp EEG, ECG, and surface EMG, which can be combined for an algorithm and implemented into devices. The daily work of clinicians may be significantly improved by the use of an automated long-term EEG review. This was described by Koren et al. as an automatic critical care EEG pattern detection method that would be helpful in reducing review times.
This Research Topic presents a compilation of different studies which increases the visibility of the high burden associated with epilepsy, along with providing some directions as to how personalized or precision approaches may help to overcome this burden. In the coming years we will see a dramatic increase in personalized or precision medicine, Figure 1, that will significantly contribute to the management of epilepsy.
Statements
Author contributions
All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
JosephsonCBPattenSBBullochAWilliamsJVALavoratoDFiestKMet al. The impact of seizures on epilepsy outcomes: a national, community-based survey. Epilepsia (2017) 58:764–71. 10.1111/epi.13723
2.
StrzelczykAReeseJPDodelRHamerHM. Cost of epilepsy: a systematic review. Pharmacoeconomics (2008) 26:463–76. 10.2165/00019053-200826060-00002
3.
BauerSvan AlphenNBeckerAChiocchettiADeichmannRDellerTet al. Personalized translational epilepsy research - Novel approaches and future perspectives: part II: experimental and translational approaches. Epilepsy Behav. (2017) 76:7–12. 10.1016/j.yebeh.2017.06.040
4.
RosenowFvan AlphenNBeckerAChiocchettiADeichmannRDellerTet al. Personalized translational epilepsy research - Novel approaches and future perspectives: part I: clinical and network analysis approaches. Epilepsy Behav. (2017) 76:13–8. 10.1016/j.yebeh.2017.06.041
5.
ReifPSTsaiMHHelbigIRosenowFKleinKM. Precision medicine in genetic epilepsies: break of dawn?Expert Rev Neurother. (2017) 17:381–92. 10.1080/14737175.2017.1253476
6.
SmeetsVMvan LieropBAVanhoutvinJPAldenkampAPNijhuisFJ. Epilepsy and employment: literature review. Epilepsy Behav. (2007) 10:354–62. 10.1016/j.yebeh.2007.02.006
7.
JacobyA. Stigma, epilepsy, and quality of life. Epilepsy Behav. (2002) 3:10–20. 10.1016/S1525-5050(02)00545-0
8.
PukaKSmithMLMoineddinRSneadOCWidjajaE. The influence of socioeconomic status on health resource utilization in pediatric epilepsy in a universal health insurance system. Epilepsia (2016) 57:455–63. 10.1111/epi.13290
9.
RiechmannJStrzelczykAReeseJPBoorRStephaniULangnerCet al. Costs of epilepsy and cost-driving factors in children, adolescents, and their caregivers in Germany. Epilepsia (2015) 56:1388–97. 10.1111/epi.13089
10.
WillemsLMRichterSWatermannNBauerSKleinKMReeseJPet al. Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 - A ten-year overview. Epilepsy Behav. (2018) 83:28–35. 10.1016/j.yebeh.2018.03.025
11.
StrzelczykABergmannABiermannVBrauneSDieterleLForthBet al. Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. Epilepsy Behav. (2016) 64(Pt A):75–82. 10.1016/j.yebeh.2016.07.037
12.
TaylorRSSanderJWTaylorRJBakerGA. Predictors of health-related quality of life and costs in adults with epilepsy: a systematic review. Epilepsia (2011) 52:2168–80. 10.1111/j.1528-1167.2011.03213.x
13.
KortlandLMKnakeSvon PodewilsFRosenowFStrzelczykA. Socioeconomic outcome and quality of life in adults after status epilepticus: a multicenter, longitudinal, matched case-control analysis from Germany. Front Neurol. (2017) 8:507. 10.3389/fneur.2017.00507
14.
StrzelczykAKleinKMWillemsLMRosenowFBauerS. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. (2016) 9:637–45. 10.1586/17512433.2016.1156529
15.
SteinhoffBJBacherMBucurenciuIHillenbrandBIntravoothTKornmeierRet al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey. Seizure (2017) 48:11–4. 10.1016/j.seizure.2017.03.010
16.
SteinigIvon PodewilsFModdelGBauerSKleinKMPauleEet al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia (2017) 58:1208–16. 10.1111/epi.13768
17.
StrzelczykAKayLBauerSImmischIKleinKMKnakeSet al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia (2018) 59:1549–56. 10.1111/epi.14476
18.
SamokhvalovAVIrvingHMohapatraSRehmJ. Alcohol consumption, unprovoked seizures, and epilepsy: a systematic review and meta-analysis. Epilepsia (2010) 51:1177–84. 10.1111/j.1528-1167.2009.02426.x
19.
HelmstaedterCWittJA. Epilepsy and cognition - A bidirectional relationship?Seizure (2017) 49:83–9. 10.1016/j.seizure.2017.02.017
20.
ThurmanDJHesdorfferDCFrenchJA. Sudden unexpected death in epilepsy: assessing the public health burden. Epilepsia (2014) 55:1479–85. 10.1111/epi.12666
21.
RyvlinPNashefLLhatooSDBatemanLMBirdJBleaselAet al. Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurol. (2013) 12:966–77. 10.1016/S1474-4422(13)70214-X
Summary
Keywords
epilepsy, seizure, anticonvulsant, antiepileptic drug (AED), quality of life, imaging
Citation
Strzelczyk A, Klein KM and von Podewils F (2019) Editorial: Burden of Illness in People With Epilepsy: From Population-Based Studies to Precision Medicine. Front. Neurol. 9:1164. doi: 10.3389/fneur.2018.01164
Received
16 September 2018
Accepted
17 December 2018
Published
09 January 2019
Volume
9 - 2018
Edited and reviewed by
Fernando Cendes, Universidade Estadual de Campinas, Brazil
Updates
Copyright
© 2019 Strzelczyk, Klein and von Podewils.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Adam Strzelczyk strzelczyk@med.uni-frankfurt.de
This article was submitted to Epilepsy, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.